URSODEOXYCHOLIC ACID (UDCA) IN PRIMARY BILIARY CIRRHOSIS

熊去氧胆酸 (UDCA) 在原发性胆汁性肝硬化中的应用

• 批准号: 7606304
• 负责人: MARLYN J MAYO
• 金额: $ 0.05万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606304
• 关键词: Affect; Albumins; Alkaline Phosphatase; Ascites; Aspartate Transaminase; Bile Acids; Bile fluid; Bilirubin; Cessation of life; Chronic; Clinical; Computer Retrieval of Information on Scientific Projects Database; Detergents; Development; Disease; Edema; Encephalopathies; Enrollment; Esophageal Varix; Fatigue; Funding; Grant; Histologic; Immunoglobulin M; Institution; Liver; Liver Failure; Liver diseases; Medical; Patients; Placebos; Primary biliary cirrhosis; Prothrombin time assay; Pruritus; Research; Research Personnel; Resources; Safety; Source; Symptoms; Toxic effect; Transplantation; United States National Institutes of Health; Ursodeoxycholic Acid

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that frequently leads to liver failure and death. No accepted form of medical therapy currently exists for this disease. Accumulation of toxic bile acids may perpetuate liver damage in PBC. Ursodeoxycholic acid is a non-toxic bile acid with decreased detergent power that can be used to alter the composition of bile favorably when given orally. Study aims are to 1) compare effects of UDCA versus placebo on alkaline phosphatase, aspartate aminotransferase, bilirubin, albumin, immunoglobulin M, and prothrombin time; 2) evaluate effects on symptoms such as fatigue and pruritus; 3) determine effects on development or clinical progression of esophageal varices, ascites or edema, and encephalopathy; 4) determine effects on histologic changes at 2 years; 5) determine whether UDCA favorably affects survival or need for transplantation; 6) assess toxicity amp; determine safety. This study is complete and no further patients will be enrolled.

这个子项目是众多研究子项目之一